Abeona Therapeutics Inc. Common Stock (ABEO)

FairStock Score: 50/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Abeona is not that today. It is a commercial-stage gene and cell therapy company with 226 employees, with ZEVASKYN as its lead product and ABO-503, ABO-504, and ABO-505 in development. Revenue is inflecting: filed fiscal Q1 2026, the quarter ended 2026-03-31, was $8.7M, and fiscal Q2 2026, the quarter ended 2026-06-30, was $11.4M, versus FY2025 revenue of $5.8M and FY2023 revenue of $3.5M. That is real commercial progress. But the bottom line is ugly: fiscal Q1 2026 net loss was $17.1M, or -$0.30 per diluted share, and fiscal Q2 2026 net loss was $20.2M, or -$0.35. Trailing free cash flow is -$81.5M, a FairStock-calculated FCF yield of -31.5% on the $258.5M market cap at the 2026-10-13 close. The balance sheet has low debt, with D/E 0.16, but FairStock's Altman Z-score is -2.32 and Piotroski F-score is 4/9, suggesting fragility. ROE is -43.13% and ROCE is -24.55%. The reported FY2025 net income of $71.2M and fiscal Q2 2025 net income of $108.8M on only $400,000 revenue look non-recurring and do not reflect core operations. P/B is 2.02, P/E is negative, and EV/EBITDA of 3.03 is distorted. The FairStock Lynch category is TURNAROUND because it returned to profit after a loss within the last three years. The FairStock Score is 50/100. A true moat is not yet evident; reimbursement, competition, and pipeline execution remain key. At $4.52, near the low end of the $4.00-$7.65 52-week range, the price may reflect hope as much as proven value.

In plain English: Abeona makes gene and cell treatments for serious skin and eye diseases. The company is selling product and revenue is growing, but it is still losing money and using cash. At $4.52 a share, the price looks fair to speculative rather than clearly cheap, because profits are not yet steady.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer